ImmunoCellular Therapeutics Ltd (NYSEAMERICAN:IMUC) was the recipient of a significant decrease in short interest during the month of January. As of January 12th, there was short interest totalling 2,260,706 shares, a decrease of 2.9% from the December 29th total of 2,327,867 shares. Approximately 6.4% of the company’s shares are sold short. Based on an average trading volume of 1,186,555 shares, the short-interest ratio is presently 1.9 days.

ImmunoCellular Therapeutics (IMUC) opened at $0.28 on Friday. The company has a market cap of $6.35, a PE ratio of -0.09 and a beta of 1.03. ImmunoCellular Therapeutics has a one year low of $0.17 and a one year high of $3.68.

ImmunoCellular Therapeutics (NYSEAMERICAN:IMUC) last announced its quarterly earnings results on Tuesday, November 21st. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter.

TRADEMARK VIOLATION NOTICE: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at

About ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company’s cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing.

Receive News & Ratings for ImmunoCellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics and related companies with's FREE daily email newsletter.